Sunrest Lifescience Limited

As of March 31, 2025, Sunrest Lifescience Limited carries a market capitalization of 277.30M, placing it among publicly traded companies globally. Its enterprise value stands at 433.61M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of March 31, 2025, Sunrest Lifescience Limited has 5.16M shares outstanding.

These figures are as of March 31, 2025.

As of March 31, 2025, Sunrest Lifescience Limited maintains a current ratio of 1.73, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended March 31, 2025.

As of the close on October 21, 2026, Sunrest Lifescience Limited's stock has declined approximately 20.45% over the past 52 weeks. The 50-day moving average sits at 37.83, while the 200-day moving average is 42.46.

As of March 31, 2025, Sunrest Lifescience Limited holds 17.38M in cash and equivalents against 120.50M in total debt, resulting in a net debt position of 103.12M. Total book value stands at 163.11M, with working capital of 226.45M providing operational flexibility.